Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
National and Kapodistrian University of Athens · Nantes Université · +33 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
843
total citations
- FWCI
- 57.64
- Percentile
- 100%
- References
- 26
Citations per year
Authors
31Topics & keywords
Topics
Keywords
- Carfilzomib
- Medicine
- Bortezomib
- Dexamethasone
- Multiple myeloma
- Clinical endpoint
- Internal medicine
- Refractory (planetary science)
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.